Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma
Background:
The efficacy of a traditional anticancer drug is challenged by adverse effects of the drug, including its nonspecific bio-distribution, short half-life, and side effects. Dendrimer-based targeted drug delivery system has been considered a promising strategy to increase targeting ability and reduce adverse effects of anti-cancer drugs.
Objective:
This study analyzed the feasibility of whether the anticancer drug 5-fluorouracil (5-FU) could be delivered by functionalized fifth-poly(amidoamine) (PAMAM) with the peptide WP05 and the acetic anhydride to the liver cancer cells, reducing the toxicity of the PAMAM and improving the targeting property of 5-FU during delivery.
Methods:
The functionalized PAMAM-based nanoformulation (WP05-G5.0NHAC-FUA) was fabricated through an amide condensation reaction to improve the therapeutic efficacy of 5-Fluorouracil (5-FU) in hepatocellular carcinoma (HCC). The physicochemical structure, particle size, zeta potential, stability, and in vitro release characteristics of WP05-G5.0NHAC-FUA were evaluated. In addition, the targeting, biocompatibility, anti-proliferation, and anti-migration of WP05-G5.0NHAC-FUA were investigated. The anti-tumor effect of WP05-G5.0NHAC-FUA in vivo was evaluated by constructing xenograft tumor models of human hepatoma cells (Bel-7402) implanted in nude mice.
Results:
The resultant WP05-G5.0NHAC-FUA displayed spherical-like nanoparticles with a size of 174.20 ± 3.59 nm. Zeta potential and the drug loading of WP05-G5.0NHAC-FUA were 5.62 ± 0.41mV and 28.67 ± 1.25%, respectively. Notably, the optimized 5-FU-loaded formulation showed greater cytotoxicity with an IC50 of 30.80 ± 4.04 μg/mL than free 5-FU (114.93 ± 1.43 μg/mL) in Bel-7402 cancer liver cells, but a significantly reduced side effect relative to free 5-FU in L02 normal liver cells. In vivo animal study further confirmed efficient tumor accumulation and enhanced therapeutic efficiency.
Conclusion:
The developed nanoformulation is a promising platform for the targeting delivery of 5-FU and provides a promising solution for improving the efficacy of hepatocellular carcinoma chemotherapy.
Top-30
Journals
|
1
|
|
|
Current Opinion in HIV and AIDS
1 publication, 10%
|
|
|
Biomedicine and Pharmacotherapy
1 publication, 10%
|
|
|
Advances in Colloid and Interface Science
1 publication, 10%
|
|
|
Drug Delivery and Translational Research
1 publication, 10%
|
|
|
Clinics and Research in Hepatology and Gastroenterology
1 publication, 10%
|
|
|
Frontiers in Pharmacology
1 publication, 10%
|
|
|
Journal of Biomaterials Science, Polymer Edition
1 publication, 10%
|
|
|
Colloid and Polymer Science
1 publication, 10%
|
|
|
Molecular Cancer
1 publication, 10%
|
|
|
1
|
Publishers
|
1
2
3
4
|
|
|
Springer Nature
4 publications, 40%
|
|
|
Elsevier
3 publications, 30%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 10%
|
|
|
Frontiers Media S.A.
1 publication, 10%
|
|
|
Taylor & Francis
1 publication, 10%
|
|
|
1
2
3
4
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.